Enliven Therapeutics (NASDAQ:ELVN) Announces Earnings Results

Enliven Therapeutics (NASDAQ:ELVN) issued its earnings results on Thursday. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09, FiscalAI reports.

Enliven Therapeutics Stock Up 10.4%

NASDAQ ELVN traded up $4.64 on Friday, reaching $49.43. The stock had a trading volume of 969,641 shares, compared to its average volume of 1,622,008. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32. The stock has a fifty day moving average price of $47.25 and a two-hundred day moving average price of $43.08. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34.

Insider Buying and Selling at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Monday, October 19th. The stock was sold at an average price of $38.48, for a total transaction of $231,572.64. Following the completion of the transaction, the chief financial officer directly owned 38,000 shares in the company, valued at $1,462,240. This trade represents a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at approximately $606,710. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 31,054 shares of company stock worth $1,493,823 in the last quarter. Company insiders own 3.00% of the company’s stock.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several analyst reports. The Goldman Sachs Group lifted their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Thursday, October 15th. Guggenheim reiterated a “buy” rating and issued a $78.00 price objective on shares of Enliven Therapeutics in a research report on Friday. Zacks Research cut Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Finally, Morgan Stanley started coverage on Enliven Therapeutics in a research note on Friday, October 2nd. They set an “overweight” rating and a $70.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $75.44.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.